Monday, December 6, 2021
49.6 F
Fort Worth

New Technology Accesses Small But Mighty Microorganisms

🕐 2 min read

(NewsUSA) – More medicines may be developed faster in the near future, thanks to new technology that harnesses the tiny particles that make drug development possible.

Microorganisms grown in laboratories have been the starting point for many medicines we have today. However, many more microorganisms exist in nature that can’t be grown in a lab because they are too small, too fragile, or evolve too rapidly. Also, microbes grown in culture behave differently than those extracted from the natural world, and are more limited in their ability to perform the chemical reactions that lead to drug discovery and product development.

But Biosortia Pharmaceuticals has developed a novel way to access the previously hidden chemistry of microorganisms and capture small molecules directly from nature.

Biosortia uses its technology to collect microbiomes in quantity and at quality, a concept known as microbiome mining. The microbiomes are becoming part of Biosortia’s growing library of patentable natural molecule activity and derivatives that can be used by various industries, including pharmaceutical, cosmetic, and agricultural, to solve problems and create products.

“Microbes are and have always been chemical researchers and factories of life,” says Ross Youngs, founder and CEO of Biosortia.

The ability of Biosortia to recover active microbiomes is creating “massive opportunities to explore the unknown,” he says in a recent LinkedIn post.

Biosortia’s microbiome mining approach has several advantages:

– More options. Biosortia’s technology allows the company unprecedented access to previously unavailable molecules that have the potential for use in a range of industries, and can provide a genomic roadmap to accompany data on the activity of the chemistry.

– More efficiency. Biosortia accesses material from the microbiome in days, compared to the years needed by other researchers. In addition, the cost of Biosortia technology is significantly lower than traditional methods of microorganism development.

– More success. Small molecules accessed directly from the microbiome are more likely to be successful in clinical development than those cultured in a lab because they have reached their potential in nature.

Biorsortia continues to expand and has secured four patents to date, as well as a pending contract with the Department of Homeland Security. The Company’s science team publication technology has been peer-reviewed and received an Editor’s Choice Award from the American Chemical Society.

For more information, visit fundable.com/biosortia.

Related Articles

Our Digital Sponsors

Latest Articles

Fort Worth Business Press Logo
This advertisement will close in
00
Months
00
Days
00
Hours
00
Minutes
00
Seconds
seconds..
Click here to continue to Fort Worth Business Press

Not ready to subscribe?

Try a few articles on us.

Enter your email address and we will give you access to three articles a month, to give us a try. You also get an opportunity to receive our newsletter with stories of the day.

This field is for validation purposes and should be left unchanged.

Get our email updates

Stay up-to-date with the issues, companies and people that matter most to business in the Fort Worth.

  • Restaurants
  • Technology
  • and more!

FWBP Morning Brief

FWBP 5@5

Weekend Newsletter

  • Banking & Finance
  • Culture
  • Real Estate